A 62-year-old man with moderate COPD presents with persistent dyspnea during daily activities despite 3 months of tiotropium monotherapy and good adherence. Vital signs: BP 138/82 mmHg, HR 94/min, RR 18/min, SpO2 92% on room air. FEV1 is 58% predicted. Chest X-ray shows no acute infiltrates. He denies orthopnea and has no lower extremity edema. Which pharmacologic agent best represents the next step in management according to GOLD guidelines?
- A)Add a long-acting beta-2 agonist (LABA) to create a dual long-acting bronchodilator combinationGABARITO
- B)Add theophylline as a second-line agent to potentiate bronchodilation
- C)Add inhaled corticosteroids as monotherapy without additional bronchodilators
- D)Refer for lung transplant evaluation given persistent symptoms on long-acting therapy
- E)Switch to short-acting bronchodilators only due to beta-blocker contraindication concerns
Explicação
According to GOLD guidelines, for patients with persistent symptoms on monotherapy with a long-acting anticholinergic (tiotropium), the next step is to add a long-acting beta-2 agonist (LABA), creating dual long-acting bronchodilator therapy (LAMA/LABA combina... Ver explicação completa e trilha adaptativa →